CytoSorbents Corporation - רווח נקי למניה בארבעת הרבעונים האחרונים CTSO

This daily price chart for Cytosorbents (CTSO) illustrates the EPS (TTM) trend, which currently stands at -60.80. Cytosorbents (CTSO) relies on an extensive distribution network for blood filtration systems across US and European clinics, ensuring high margins. Automated assembly guarantees high product quality, although device operation requires medical supervision. The business is currently focusing on the development of Purifi to combat cytokine storms.

This indicator measures the dynamics of net income per share over a rolling year, allowing for an assessment of capital generation efficiency relative to the previous period. For the non-cyclical emergency medicine business of Cytosorbents (CTSO), the EPS growth rate over the last 12 months YoY serves as a marker of fundamental stability, where any narrowing of volatility amplitude may signal a risk of revenue stagnation.